US 9476052
RNAi inhibition of alpha-ENaC expression
granted A61KA61K31/713A61K45/06
Quick answer
US patent 9476052 (RNAi inhibition of alpha-ENaC expression) held by Arrowhead Pharmaceuticals, Inc. expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/713, A61K45/06, A61P, A61P11/00